Inclusive Capital Partners is contemplating the sale of its stake in Bayer, three years after initially revealing its investment in the company. Bloomberg posted on X, highlighting the potential move by the investment firm led by activist Jeff Ubben. Inclusive Capital Partners had previously disclosed its holding in Bayer, marking a significant investment in the pharmaceutical and life sciences company. The decision to sell comes amid ongoing evaluations of the firm's investment strategies and market conditions. Bayer, known for its diverse portfolio in health care and agriculture, has been a focal point for investors seeking growth opportunities in these sectors. The potential sale by Inclusive Capital Partners could impact Bayer's shareholder dynamics and influence its strategic direction moving forward. As the situation develops, market observers are keenly watching for further announcements from the investment firm regarding its plans and the implications for Bayer's future.